The BiliSeq molecular test developed at UPMC doubled detection sensitivity for bile duct cancer compared to standard pathology.
Key Details
- 1BiliSeq detected 82% of bile duct cancers vs. 44% with pathology alone in a six-year, multi-center study of over 2,000 patients.
- 2Combining BiliSeq with pathology increased detection up to 90% while minimizing false positives for benign disease.
- 3The test identifies actionable genetic mutations in about 20% of patients, informing care changes in nearly a third of those cases.
- 4BiliSeq maintains high performance in at-risk subgroups, detecting up to 86% of cancers in high-risk patients like those with PSC.
- 5Results have direct implications for diagnosis clarification and treatment—including transplant decisions—where imaging and standard biopsies often fail.
Why It Matters
This study demonstrates transformative potential for molecular diagnostics to support radiology and pathology in challenging cancer cases, reducing uncertainty for clinicians and patients. Enhanced diagnostic accuracy may lead to faster, more tailored interventions, especially in hard-to-assess biliary cancers.
Source
EurekAlert
Related News
•EurekAlert
AI Analyzes 66,000 MRI Scans to Map Body Composition Risks
Researchers used AI to analyze over 66,000 whole-body MRI scans, creating a detailed body composition reference map linked to health risks.
•EurekAlert
Brain-Inspired Training Enhances AI Reliability and Uncertainty Recognition
KAIST researchers developed a brain-inspired AI training method that reduces overconfidence and improves the recognition of unfamiliar data.
•EurekAlert
AI and PS-OCT Enhance Early Keratoconus Detection
AI combined with polarization-sensitive OCT enables earlier and more accurate detection of subclinical keratoconus compared to standard tomography.